BVF Inc’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

BVF Inc’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,758	Closed	-$5.91M	–	60
2018 Q2	$5.91M	Sell	2,758 -1,597	-37%	-$4.05M	0.58%	39
2018 Q1	$10.8M	Sell	4,355 -3,555	-45%	-$7.92M	1.1%	26
2017 Q4	$14.1M	Sell	7,910 -7	-0.1%	-$10.1K	1.7%	18
2017 Q3	$9.11M	Hold	7,917	–	–	1.16%	25
2017 Q2	$5.86M	Hold	7,917	–	–	0.91%	25
2017 Q1	$5.39M	Hold	7,917	–	–	0.92%	25
2016 Q4	$5.85M	Sell	7,917 -306	-4%	-$327K	1.18%	21
2016 Q3	$9.01M	Hold	8,223	–	–	1.7%	18
2016 Q2	$6.33M	Hold	8,223	–	–	1.35%	20
2016 Q1	$5.76M	Buy	8,223 +249	+3%	+$216K	1.42%	21
2015 Q4	$7.81M	Buy	7,974 +279	+4%	+$369K	1.33%	21
2015 Q3	$8.19M	Hold	7,695	–	–	1.65%	18
2015 Q2	$15.8M	Sell	7,695 -242	-3%	-$344K	2.79%	14
2015 Q1	$7.51M	Hold	7,937	–	–	1.57%	18
2014 Q4	$8.11M	Buy	+7,937	New	+$7.08M	1.58%	18

Other funds holding ONCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BVF Inc's ONCT Position: Q3 2018 in Review

BVF Inc sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2018, closing a stake of 2,758 shares — an estimated $5.91M sold.

BVF Inc first reported a position in ONCT in Q4 2014 and held it in 15 quarters. The position peaked at $15.8M in Q2 2015. 48 funds tracked by Wall St. Rank hold ONCT as of Q3 2018.

BVF Inc reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
BVF Inc sold 2,758 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $5.91M.
BVF Inc first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2014 and held it in 15 quarters.
BVF Inc's Oncternal Therapeutics, Inc. Common Stock position peaked at $15.8M in Q2 2015.
48 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2018.

Based on BVF Inc's 13F filing for Q3 2018, filed 14 Nov 2018.